![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Bioventrix’s Transcatheter Heart Device Gains FDA Breakthrough Status
Bioventrix’s Transcatheter Heart Device Gains FDA Breakthrough Status
![](https://www.fdanews.com/ext/resources/test/Device_Images6/Bioventrix_Logo.png?t=1576044196&width=430)
The FDA has granted breakthrough device designation status to Bioventrix’s Revivent TC, a transcatheter-based structural heart device, for treating heart failure.
The device is used during less invasive ventricular enhancement (LIVE) procedures to exclude scar tissue in the left ventricle caused by a heart attack, allowing the healthy part of the heart to function more effectively.
During the procedure, anchors are placed and set to shape the heart into a more normal form and size, taking stress off its walls and potentially improving blood flow through the body.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct